Insulet Corporation (PODD) is an independent, publicly traded medical device company, meaning it is owned by its shareholders rather than a single individual or parent corporation. After its initial public offering, the company has operated under the leadership of its own Board of Directors and executive team, focusing on the development and commercialization of its proprietary insulin delivery products. The company’s ownership is highly dispersed, with a significant majority of its common stock held by major institutional investment firms, such as index fund providers and large-scale mutual fund managers. This structure ensures that no single entity holds absolute control; instead, the company is governed by professional management accountable to the public market and its diverse, global shareholder base, who collectively influence the firm's strategic focus on diabetes innovation, operational efficiency, and sustainable long-term revenue growth.